Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

Antimicrobial Agents and Chemotherapy
Clifford G BandaVictor Mwapasa

Abstract

There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus-infected (HIV+) individuals receiving antiretroviral therapy. In a two-step intensive sampling pharmacokinetic trial, we compared the area under the concentration-time curve from 0 to 28 days (AUC0-28) of an active metabolite of amodiaquine, desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-naive HIV+ adults and those taking nevirapine and ritonavir-boosted lopinavir-based antiretroviral therapy. In step 1, malaria-uninfected adults (n = 6/arm) received half the standard adult treatment regimen of artesunate-amodiaquine. In step 2, another cohort (n = 25/arm) received the full regimen. In step 1, there were no safety signals or significant differences in desethylamodiaquine AUC0-28 among participants in the ritonavir-boosted lopinavir, nevirapine, and antiretroviral therapy-naive arms. In step 2, compared with those in the antiretroviral therapy-naive arm, participants in the ritonavir-boosted lopinavir arm had 51% lower desethylamodiaquine AUC0-28, with the following geometric means (95% confidence intervals [CIs]): 23,822 (17,458 to 32,506) versus 48,617 (40,787 t...Continue Reading

References

Jan 1, 1991·International Archives of Allergy and Applied Immunology·J B ClarkeB K Park
Jun 1, 1990·British Journal of Clinical Pharmacology·P A WinstanleyA M Breckenridge
Mar 19, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·L I Malaty, J J Kuper
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Xue-Qing LiCollen M Masimirembwa
Apr 3, 2003·HIV Clinical Trials·Luz Martín-CarboneroVincent Soriano
Oct 1, 2003·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·L S Fridericia
Feb 18, 2005·The Journal of Infectious Diseases·Ian SanneFranck Rousseau
Oct 29, 2005·BMC Clinical Pharmacology·Ina BergheimAlexandr Parlesak
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheryl CohenHeather Crewe-Brown
Feb 16, 2006·The Journal of Infectious Diseases·Miriam K LauferChristopher V Plowe
Sep 9, 2006·The Journal of Infectious Diseases·Jean-Pierre Van GeertruydenUmberto D'Alessandro
Feb 17, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Polina GermanFrancesca T Aweeka
Jul 11, 2007·Journal of Pharmacokinetics and Pharmacodynamics·Sofia Friberg HietalaMichael Ashton
Jan 16, 2008·Clinical Pharmacokinetics·Polina I German, Francesca T Aweeka
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anne F GasasiraGrant Dorsey
May 1, 2009·Emerging Infectious Diseases·Victor ChalweUmberto D'Alessandro
May 30, 2009·Archives of Toxicology·Shinji ShimizuOsamu Okazaki
Aug 21, 2009·Malaria Journal·Kasia StepniewskaJean-René Kiechel
Oct 21, 2009·Antimicrobial Agents and Chemotherapy·Julia MwesigwaFrancesca Aweeka
Jun 29, 2011·Antimicrobial Agents and Chemotherapy·Marcus J RijkenFrançois Nosten
Apr 19, 2015·BMC Medicine·UNKNOWN WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study GroupIssaka Zongo

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.